CDK4 and neoplasm: A recent report from our institutional LIBERATE cohort study, which included 51 patients with HR+/HER2− MBC receiving standard ET and CDK4/6i evaluated ctDNA detection and dynamics using a high-sensitivity tumor-informed assay.